<!DOCTYPE html>
<html>
    <head>
        <title>5</title>

    </head>
    <body>
        <div data-role="page" id="c5-t" data-theme="a">
            <div data-id="quickpick-header" data-role="header" data-theme="b" data-position="fixed"><a href="c3-clv.html" class="ui-btn ui-icon-back ui-btn-icon-notext ui-corner-all" aria-label="back"></a>
                <h1>Condition Quick Pick</h1>
        <a href="../menu.html" class="ui-btn ui-icon-grid ui-btn-icon-notext ui-corner-all" aria-label="main menu"></a>    </div>
            <div data-role="content" data-theme="a" >
                <div id=quickpick_breadcrumbs>
                
                        <a href="c0-clv.html" >Condition Quick Pick</a><span class="carrot"> > </span>
                        <a href="c3-clv.html" >Candidiasis - Vulvovaginal</a><span class="carrot"> > </span>Complicated
                </div>   <!-- end of quick pick breadcrumbs -->
                </br><h5 class="sgc-1" id="sigil_toc_id_289">
 Treatment
</h5>
<p>
 Each individual episode of RVVC caused by
 <i>
  C. albicans
 </i>
 responds well to short-duration oral or topical azole therapy. However, to maintain clinical and mycologic control, some specialists recommend a longer duration of initial therapy (e.g., 7&ndash;14 days of topical therapy or a 100-mg, 150-mg, or 200-mg oral dose of fluconazole every third day for a total of 3 doses [day 1, 4, and 7]) to attempt mycologic remission before initiating a maintenance antifungal regimen.
</p>
<h5 class="sgc-1" id="sigil_toc_id_290">
 Maintenance Regimens
</h5>
<p>
 Oral fluconazole (i.e., 100-mg, 150-mg, or 200-mg dose) weekly for 6 months is the first line of treatment. If this regimen&nbsp;is not feasible, topical treatments used intermittently as a maintenance regimen can be considered.
</p>
<p>
 Suppressive maintenance antifungal therapies are effective in reducing RVVC. However, 30%&ndash;50% of women will have recurrent disease after maintenance therapy is discontinued. Routine treatment of sex partners is controversial.
 <i>
  C. albicans
 </i>
 azole resistance is rare in vaginal isolates, and susceptibility testing is usually not warranted for individual treatment guidance.
</p>
<h4 class="sgc-1" id="sigil_toc_id_291">
 Severe VVC
</h4>
<p>
 Severe vulvovaginitis (i.e., extensive vulvar erythema, edema, excoriation, and fissure formation) is associated with lower clinical response rates in patients treated with short courses of topical or oral therapy. Either 7&ndash;14 days of topical azole or 150 mg of fluconazole in two sequential doses (second dose 72 hours after initial dose) is recommended.
</p>
<h4 class="sgc-1" id="sigil_toc_id_292">
 Nonalbicans VVC
</h4>
<p>
 The optimal treatment of nonalbicans VVC remains unknown. Options include longer duration of therapy (7&ndash;14&nbsp;days) with a nonfluconazole azole drug (oral or topical) as first-line therapy. If recurrence occurs, 600 mg of boric acid in a gelatin capsule is recommended, administered vaginally once daily for 2 weeks. This regimen has clinical and mycologic eradication rates of approximately 70% (380). If symptoms recur, referral to a specialist is advised.
</p>

            <div data-role="footer" data-id="regimens-footer" data-position="fixed" class="tab_treatment">
                <div data-role="navbar" class="tab_icons" data-iconpos="left">
                    <ul>
                        <li><a href="#" class="ui-disabled" id="treat_inactive" data-theme="a" data-icon="custom">Treatments</a></li>
                        <li><a href="#" id="info_active" data-theme="b" class="ui-btn-active ui-state-persist" data-icon="custom">More Info</a></li>
                    </ul>
                </div>
            </div>

        </div>
    </div>
</body>
</html>
